Study purpose:

The primary purpose of the Phase 3 study is to evaluate the therapeutic efficacy of Rel-1017 compared to placebo in subjects with Major Depressive Disorder (MDD) with inadequate response to ongoing antidepressants therapy (ADT)

What is the medication?

Rel-1017. Participants will be asked to stay on a stable dosing regimen of their current ADT during the treatment period while exposed to Rel-107

Overview:

Screening period: up to 30 days

Treatment period: 4 weeks

All those who complete the 4 week treatment period will be given the opportunity to enroll in a 1 year open label study in which you would be guaranteed to receive study medication

You May Qualify If:

You have been diagnosed with MDD, are in a major depressive episode, and have been treated for at least 6 weeks prior to screening with an approved antidepressant therapy (ADT) and experiencing a <50% improvement on the approved regimen of ADT

Qualified candidates may earn up to ____ per visit. Transportation assistance to those who enroll.